Central nervous system (CNS) Cluster Addiction Drug Development Pipeline Review 2017 provides comprehensive information on the therapeutics under development, and key players involved in therapeutic development for Alcohol Addiction, Drug Addiction, Nicotine Addiction, Opium (Opioid) Addiction and features dormant and discontinued projects. Central nervous system (CNS) Cluster Addiction Drug Development report provides companies which are the most active within the pipeline for addiction therapeutics and pharmaceutical approaches that are the most prominent at each stage of the pipeline and within each indication. It also provides comprehensive information on universities and institutions role within this pipeline, compared to pharmaceutical companies and most important R&D milestones and data publications to have happened in the field of addiction therapeutics.
Request Sample Report at: http://www.reportsnreports.com/contacts/requestsample.aspx?name=1001381 .
Alcohol addiction refers to a psychological and physical dependency on alcohol. Symptoms include decreased involvement in extracurricular activities, depression, and restlessness, inability to control drinking and violent behavior. There are a total of 38 products in development for this indication, by 29 companies and five academic institutions. Key companies operating in this pipeline space include Abbvie, Astraea Therapeutics, Lochola Research and SK Biopharmaceuticals.
Report includes Alcohol Addiction Pipeline by key Companies Addex Therapeutics Ltd, Adial Pharmaceuticals LLC, Astraea Therapeutics LLC, BioCorRx Inc, Bionex Pharmaceuticals LLC, Bioprojet SCR, Cerecor Inc, Chronos Therapeutics Ltd, Corcept Therapeutics Inc, Curemark LLC, Eli Lilly and Company, Ethypharm SA, Euthymics Bioscience Inc, H. Lundbeck A/S, Heptares Therapeutics Ltd, Indivior Plc, Kinnov Therapeutics SAS, Kyorin Pharmaceutical Co Ltd, Lohocla Research Corp, Omeros Corp, Pfizer Inc, Savant HWP Inc, SK Biopharmaceuticals Co Ltd, Tonix Pharmaceuticals Holding Corp, VM Discovery Inc, XenoPort Inc, Zynerba Pharmaceuticals Inc.
Purchase Licensed Copy of This Report at http://www.reportsnreports.com/purchase.aspx?name=1001381
Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. There are a total of 67 products in development for this indication, by 38 companies and 16 academic institutions. Key companies operating in this pipeline space include Astraea Therapeutics, Addex therapeutics, The University of Kansas, Embera NeuroTherapeutics, InterveXion Therapeutics, Omeros, Opiant Pharmaceuticals and Orexigen Therapeutics.
Report includes Drug addiction Pipeline by Addex Therapeutics Ltd, Aelis Farma SAS, Aphios Corp, Astraea Therapeutics LLC, BioCorRx Inc, Cerecor Inc, Chiesi Farmaceutici SpA, Curemark LLC, Embera NeuroTherapeutics Inc, F. Hoffmann-La Roche Ltd, Foresee Pharmaceuticals LLC, Heptares Therapeutics Ltd, Immunovaccine Inc, Indivior Plc, InterveXion Therapeutics LLC, Intra-Cellular Therapies Inc, Kyorin Pharmaceutical Co Ltd, Kyowa Hakko Kirin Co Ltd, MedRev Pharma, NLS Pharma Group,Omeros Corp, Opiant Pharmaceuticals Inc, Orexigen Therapeutics Inc,P2D Bioscience, Saniona AB, Savant HWP Inc, Stada Arzneimittel AG, Teva Pharmaceutical Industries Ltd, Zynerba P
Nicotine addiction also called tobacco dependence is an addiction to tobacco products caused by the drug nicotine. There are a total of 19 products in development for this indication, by 13 companies and 5 academic institutions. The majority of companies are developing single pipeline program in this space, while Omeros are developing two.
Report includes Nicotine addiction Pipeline by Addex Therapeutics Ltd, Astraea Therapeutics LLC, C4X Discovery Holdings PLC, Chronos Therapeutics Ltd, CV Sciences Inc, Hager Biosciences LLC, Heptares Therapeutics Ltd, Omeros Corp, Savant HWP Inc.
Get Discount on This Report at http://www.reportsnreports.com/contacts/discount.aspx?name=1001381 .
Finally opioid addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). There are a total of 33 products in development for this indication, by 23 companies and three academic institutions. Key companies operating in this pipeline space include Indivior, INSYS Therapeutics, Omeros, Pfizer and Zynerba Pharmaceuticals.
Report includes opioid addiction Pipeline by Alkermes Plc, Aoxing Pharmaceutical Company Inc, Aquilus Pharmaceuticals Inc, BioCorRx Inc, BioDelivery Sciences International Inc, Camurus AB, Foresee Pharmaceuticals LLC, Heron Therapeutics Inc, Indivior Plc, INSYS Therapeutics Inc, Omeros Corp, Opiant Pharmaceuticals Inc, Orexigen Therapeutics Inc, Orexo AB, Pfizer Inc, Relmada Therapeutics Inc, Savant HWP Inc, Teva Pharmaceutical Industries Ltd, Titan Pharmaceuticals Inc, Zynerba Pharmaceuticals Inc
There is a substantial degree of overlap between these indications in terms of the types of molecular target which are being studied. The mu and kappa-opioid receptors are the dominant molecular target across alcohol, drug and opioid addiction, and other neurotransmitter receptors such as the cannabinoid and dopamine receptors are common molecular targets across the three. In contrast, while such neurotransmitter receptors are present in the nicotine addiction pipeline, the opioid receptors are not, and the dominant molecular target is the orexin receptor type 1.
Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
Tel: + 1 888 391 5441